22nd March 2022 | Pharma Updates
Hetero received CDSCO approval to commercialise Sputnik Light vaccine
Hetero to gain Manufacturing and Marketing approval for a COVID-19 preventive medication manufactured locally and administered in a single dosage.
AstraZeneca COVID medication neutralises Omicron sub-variants
In an independent lab research, AstraZeneca reported that its antibody-based cocktail for preventing and treating COVID-19 retained neutralising activity against Omicron coronavirus variations.
Alembic's lacosamide Tablets have been approved by the USFDA
USFDA has given final approval to Alembic Pharmaceuticals’ Abbreviated New Drug Application for Lacosamide Tablets USP, 50 mg, 100 mg, 150 mg, and 200 mg.
Oasmia and Lonza signed manufacturing deal for an ovarian cancer medication
Lonza Group announced the signing of a manufacturing deal with Oasmia Pharmaceutical of Sweden for the ovarian cancer medication candidate Cantrixil.
Marinus Pharma's medication for a rare genetic form of epilepsy approved by FDA
The drug Ztalmy from Marinus Pharmaceuticals has been approved by the FDA to treat seizures in patients with CDKL5 deficiency, an inherited form of epilepsy.
Scientists discovered how a molecule can be turned into an anticancer weapon
Marizomb, is an anti-cancer chemical, phase III clinical trials for the treatment of glioblastoma. For the first time, scientists have a better understanding of the enzyme-driven process that activates the chemical.
ORYZON Announces FDA Approval of an Investigational New Drug for FRIDA
FDA has accepted Oryzon Genomics’ IND for iadademstat to begin a Phase Ib clinical trial in patients with relapsed/refractory Acute Myeloid Leukemia who have an FMS-like tyrosine kinase mutation.
FDA reform debate sparked by contentious Alzheimer's medication approval
FDA granted conditional approval to a controversial Alzheimer’s medicine, prompting more scrutiny and a move to alter a popular regulatory procedure used to expedite the approval of cancer drugs and other treatments.
Zydus has received FDA approval to market generic mycophenolate mofetil injectable
FDA granted Zydus Lifesciences a prior approval supplement, allowing the business to market its generic mycophenolate mofetil injection USP, 500 mg vial.
Glenmark's lacosamide tablets for seizure treatment have been approved by USFDA
USFDA has given final approval to Glenmark’s lacosamide tablets, which are the generic version of Vimpat pills and are used to treat seizures.
